Global Market Study on Biopharmaceuticals: Asia to Witness Highest Growth by 2020


#320624

197pages

Persistence Market Research

$ 4900

In Stock

Biopharmaceuticals are medicinal drugs which are produced through biotechnology methods such as recombinant DNA techniques, fermentation, hybridoma techniques, and purification processes. Biopharmaceutical production involves the usage of biological sources, either live organisms or their active components. They are made up of proteins and nucleic acids and target specific diseases and patients groups. Biopharmaceuticals are used in the treatment of various chronic diseases such as cardiovascular, metabolic, neurological, cancer, and other rare diseases for which there are no available treatments. Biopharmaceuticals have lead to enhancement in the quality of healthcare and has improved the quality of life of patients. Various biopharmaceuticals used for treating such diseases are monoclonal antibodies, erythropoietin, growth hormones, recombinant proteins, recombinant human insulin, purified proteins, interferon, vaccines and other biopharmaceuticals. However, high costs of biopharmaceuticals, entry of low-cost biosimilars, and risk of side-effects posed by biopharmaceuticals act as restraints for the biopharmaceuticals market.

In terms of value, North America dominates the biopharmaceuticals market. This is due to rising research and development investments and increasing technological advancements in biopharmaceuticals in the region. The market in Asia is expected to experience a high growth rate in the near future. This is due to improving the quality of healthcare and increasing adoption of biopharmaceuticals by physicians, drug wholesalers, pharmacies, and patients in the region.

Various factors such as increasing chronic diseases, aging population, and technological advancements in biopharmaceuticals along with increasing investment in research and development by various companies has lead to the growth of the global biopharmaceuticals market. However, high costs of biopharmaceuticals, the risk of side–effects, and availability of low-cost biosimilars are restraining the growth of the global market for biopharmaceuticals.

This report provides in-depth analysis and estimation of the biopharmaceuticals market for the period 2014–2020, considering 2013 as the base year for the calculation. In addition, data pertaining to current market dynamics, including market drivers, restraints, trends, and strategic developments has been provided in the report. The biopharmaceuticals market is categorized on the basis of type, application, and geography. Based on type, the global biopharmaceuticals market can be classified as monoclonal antibodies, erythropoietin, granulocyte colony stimulating factor, purified proteins, recombinant proteins, recombinant human insulin, interferon, growth hormones, vaccines, and other biopharmaceuticals. Based on the therapeutic application, the global biopharmaceuticals can be classified as oncology, metabolic disorders, neurological disorders, cardiovascular diseases, inflammatory and infectious diseases, and other rare diseases.

In the geographical analysis, the report identifies and analyses market size and forecast of North America, Europe, Asia, and Rest of the World (RoW). North America is further segmented into the U.S., and Canada; Europe into the U.K., Germany, France, Italy, Spain, and Russia;  Asia into China, Japan, and India; and RoW into Australia and Brazil.

Some of the major players in the Biopharmaceuticals market:

  • Pfizer, Inc.
  • F. Hoffmann-La Roche AG.
  • Johnson & Johnson Services, Inc.
  • Sanofi, Amgen Inc.
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Biogen Idec.
  • Bayer AG.
  • Eli Lilly and Company.
  • Novartis AG GlaxoSmithKline Plc.
  • Bristol-Myers Squibb Company.
  • AstraZeneca PLC.
  • Abbott Laboratories.
  • Other

These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability, and financial overview.

Table of Content

Chapter 1 Preface 14
1.1 Report Description 14
1.2 Research Methodology 15
1.3 Assumptions 15


Chapter 2 Market Synopsis 17


Chapter 3 Porter’s Five Forces Analysis 19
3.1 Bargaining Power of Suppliers 19
3.2 Bargaining Power of Buyers 20
3.3 Threat of New Entrants 20
3.4 Threat of Substitutes 21
3.5 Intensity of Rivalry 21


Chapter 4 Market Overview 22
4.1 Market Definition 22
4.2 Market Drivers 26
4.2.1 Increasing aging population 26
4.2.2 Rising cases of chronic diseases 27
4.2.3 Technological advancements 28
4.2.4 Increasing R&D investments 28
4.3 Impact Analysis of Market Drivers 30
4.4 Restraints 31
4.4.1 High costs of biopharmaceuticals 31
4.4.2 Entry of low-cost biosimilars 31
4.4.3 Risk of side effects posed by biopharmaceutical drugs 32
4.5 Impact Analysis of Market Restraints 33
4.6 Opportunities 34
4.6.1 Diseases with high unmet needs 34
4.6.2 Emerging markets 34
4.6.3 Increasing new pipeline products 35
4.7 Trends 36
4.7.1 Outsourcing trends 36


Chapter 5 Global Market Size and Forecast 37


Chapter 6 Market Size and Forecast by Type 43
6.1 Monoclonal Antibodies 43
6.2 Recombinant Proteins 45
6.3 Granulocyte-Colony Stimulating Factor (G-CSF) 47
6.4 Interferons 49
6.5 Recombinant Human Insulin 51
6.6 Erythropoietin 53
6.7 Vaccines 55
6.8 Growth Hormones 57
6.9 Purified Proteins 59
6.10 Others 61


Chapter 7 Market Size and Forecast by Therapeutic Application 64
7.1 Metabolic Disorders 64
7.2 Oncology 66
7.3 Neurological Disorders 68
7.4 Cardiovascular Diseases 70
7.5 Inflammatory and Infectious Diseases 72
7.6 Others 74


Chapter 8 Market Size and Forecast by Geography 77
8.1 North America 77
8.1.1 Scenario in the U.S. 79
8.1.2 Scenario in Canada 84
8.2 Europe 90
8.2.1 Scenario in the U.K. 93
8.2.2 Scenario in Germany 98
8.2.3 Scenario in France 103
8.2.4 Scenario in Russia 108
8.2.5 Scenario in Italy 114
8.2.6 Scenario in Spain 118
8.3 Asia 123
8.3.1 Scenario in Japan 126
8.3.2 Scenario in China 130
8.3.3 Scenario in India 135
8.4 Rest of the World 140
8.4.1 Scenario in Brazil 142
8.4.2 Scenario in Australia 147


Chapter 9 Competitive Scenario 153
9.1 Competitive Benchmarking 153
9.2 Company Share Analysis 155


Chapter 10 Company Profiles 157
10.1 Abbott Laboratories 157
10.1.1 Company overview 157
10.1.2 Products and services 158
10.1.3 Financial performance 158
10.1.4 Key developments 159
10.2 Pfizer, Inc. 160
10.2.1 Company overview 160
10.2.2 Products and services 160
10.2.3 Financial performance 161
10.2.4 Key developments 161
10.3 Eli Lilly and Company 162
10.3.1 Company overview 162
10.3.2 Products and services 162
10.3.3 Financial performance 163
10.3.4 Key developments 163
10.4 Sanofi 164
10.4.1 Company overview 164
10.4.2 Products and services 164
10.4.3 Financial performance 165
10.4.4 Key developments 166
10.5 AbbVie Inc. 167
10.5.1 Company overview 167
10.5.2 Products and segments 167
10.5.3 Financial performance 168
10.5.4 Key developments 168
10.6 Novartis AG 169
10.6.1 Company overview 169
10.6.2 Products and services 170
10.6.3 Financial performance 170
10.6.4 Key developments 171
10.7 AstraZeneca plc 172
10.7.1 Company overview 172
10.7.2 Products and services 172
10.7.3 Financial performance 173
10.7.4 Key developments 173
10.8 Amgen, Inc. 175
10.8.1 Company Overview 175
10.8.2 Product and Services 175
10.8.3 Financial Performance 176
10.8.4 Recent Developments 176
10.9 Biogen Idec 178
10.9.1 Company Overview 178
10.9.2 Product and Services 178
10.9.3 Financial Performance 179
10.9.4 Recent Developments 179
10.10 GlaxoSmithKline Plc 182
10.10.1 Company overview 182
10.10.2 Products and services 182
10.10.3 Financial performance 183
10.10.4 Key developments 183
10.11 Bristol-Myers Squibb Company 185
10.11.1 Company overview 185
10.11.2 Products and services 185
10.11.3 Financial performance 186
10.11.4 Key developments 186
10.12 Bayer AG 187
10.12.1 Company overview 187
10.12.2 Products and segments 187
10.12.3 Financial performance 188
10.12.4 Key developments 188
10.13 Merck & Co., Inc. 190
10.13.1 Company overview 190
10.13.2 Products and services 190
10.13.3 Financial performance 191
10.13.4 Key developments 191
10.14 F. Hoffmann-La Roche, Ltd. 192
10.14.1 Company overview 192
10.14.2 Products and services 192
10.14.3 Financial performance 193
10.14.4 Key developments 193
10.15 Johnson & Johnson Services, Inc. 195
10.15.1 Overview 195
10.15.2 Products and Segments 195
10.15.3 Financial Performance 196
10.15.4 Strategic Development 196

TABLE 1 Market snapshot: biopharmaceuticals market, 2014 and 2020 18
TABLE 2 Drivers for biopharmaceutical market: Impact analysis 30
TABLE 3 Restraints for biopharmaceutical market: Impact analysis 33
TABLE 4 Global biopharmaceuticals market size, by region, 2010 – 2013 (USD Mn) 37
TABLE 5 Global biopharmaceuticals market size, by region, 2014 – 2020 (USD Mn) 38
TABLE 6 Global biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 39
TABLE 7 Global biopharmaceuticals market size, by usage, 2014 – 2020 (USD Mn) 40
TABLE 8 Global biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 41
TABLE 9 Global biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 42
TABLE 10 Global monoclonal antibodies market size, by region, 2010 – 2013 (USD Mn) 44
TABLE 11 Global monoclonal antibody market size, by region, 2014 – 2020 (USD Mn) 45
TABLE 12 Global recombinant proteins market size, by region, 2010 – 2013 (USD Mn) 46
TABLE 13 Global recombinant proteins market size, by region, 2014 – 2020 (USD Mn) 47
TABLE 14 Global granulocyte-colony stimulating factor market size, by region, 2010 – 2013 (USD Mn) 48
TABLE 15 Global granulocyte-colony stimulating factor market size, by region, 2014 – 2020 (USD Mn) 49
TABLE 16 Global interferons market size, by region, 2010 – 2013 (USD Mn) 50
TABLE 17 Global interferons market size, by region, 2014 – 2020 (USD Mn) 51
TABLE 18 Global recombinant human insulin market size, by region, 2010 – 2013 (USD Mn)  52
TABLE 19 Global recombinant human insulin market size, by region, 2014 – 2020 (USD Mn)  53
TABLE 20 Global erythropoietin market size, by region, 2010 – 2013 (USD Mn) 54
TABLE 21 Global erythropoietin market size, by region, 2014 – 2020 (USD Mn) 55
TABLE 22 Global vaccines market size, by region, 2010 – 2013 (USD Mn) 56
TABLE 23 Global vaccines market size, by region, 2014 – 2020 (USD Mn) 57
TABLE 24 Global growth hormones market size, by region, 2010 – 2013 (USD Mn) 58
TABLE 25 Global growth hormones market size, by region, 2014 – 2020 (USD Mn) 59
TABLE 26 Global purified proteins market size, by region, 2010 – 2013 (USD Mn) 60
TABLE 27 Global purified proteins market size, by region, 2014 – 2020 (USD Mn) 61
TABLE 28 Global other market size, by region, 2010 – 2013 (USD Mn) 62
TABLE 29 Global other market size, by region, 2014 – 2020 (USD Mn) 63
TABLE 30 Global metabolic disorders market size, by region, 2010 – 2013 (USD Mn) 65
TABLE 31 Global metabolic disorders market size, by region, 2014 – 2020 (USD Mn) 66
TABLE 32 Global oncology market size, by region, 2010 – 2013 (USD Mn) 67
TABLE 33 Global oncology market size, by region, 2014 – 2020 (USD Mn) 68
TABLE 34 Global neurological disorders market size, by region, 2010 – 2013 (USD Mn) 69
TABLE 35 Global neurological disorders market size, by region, 2014 – 2020 (USD Mn) 70
TABLE 36 Global cardiovascular diseases market size, by region, 2010 – 2013 (USD Mn) 71
TABLE 37 Global cardiovascular diseases market size, by region, 2014 – 2020 (USD Mn) 72
TABLE 38 Global inflammatory and infectious diseases market size, by region, 2010 – 2013 (USD Mn) 73
TABLE 39 Global inflammatory and infectious diseases market size, by region, 2014 – 2020 (USD Mn) 74
TABLE 40 Global others market size, by region, 2010 – 2013 (USD Mn) 75
TABLE 41 Global others market size, by region, 2014 – 2020 (USD Mn) 76
TABLE 42 The North American biopharmaceuticals market size, by country, 2010 – 2013 (USD Mn) 78
TABLE 43 The North American biopharmaceuticals market size, by country, 2014 – 2020 (USD Mn) 79
TABLE 44 The U.S. biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 81
TABLE 45 The U.S. biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 82
TABLE 46 The U.S. biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 83
TABLE 47 The U.S. biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 84
TABLE 48 Canadian biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 86
TABLE 49 Canadian biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 87
TABLE 50 The Canadian biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 88
TABLE 51 Canadian biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 89
TABLE 52 The European biopharmaceuticals market size, by country, 2010 – 2013 (USD Mn)  92
TABLE 53 The European biopharmaceuticals market size, by country, 2014 – 2020 (USD Mn)  93
TABLE 54 The U.K. biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 95
TABLE 55 The U.K. biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 96
TABLE 56 The U.K. biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 97
TABLE 57 The U.K. biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 98
TABLE 58 German biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 100
TABLE 59 German biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 101
TABLE 60 German biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 102
TABLE 61 German biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 103
TABLE 62 French biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 105
TABLE 63 French biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 106
TABLE 64 French biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 107
TABLE 65 French biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 108
TABLE 66 Russian biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 110
TABLE 67 Russian biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 111
TABLE 68 Russian biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 112
TABLE 69 Russian biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 113
TABLE 70 Italian biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 115
TABLE 71 Italian biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 116
TABLE 72 Italian biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 117
TABLE 73 Italian biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 118
TABLE 74 Spanish biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 120
TABLE 75 Spanish biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 121
TABLE 76 Spain biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 122
TABLE 77 Spain biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 123
TABLE 78 The Asian biopharmaceuticals market size, by country, 2010 – 2013 (USD Mn) 125
TABLE 79 The Asian biopharmaceuticals market size, by region, 2014 – 2020 (USD Mn) 125
TABLE 80 Japanese biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 127
TABLE 81 Japanese biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 128
TABLE 82 Japanese biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 129
TABLE 83 Japanese biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 130
TABLE 84 Chinese biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 132
TABLE 85 Chinese biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 133
TABLE 86 Chinese biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 134
TABLE 87 Chinese biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 135
TABLE 88 Indian biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 137
TABLE 89 Indian biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 138
TABLE 90 Indian biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 139
TABLE 91 Indian biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 140
TABLE 92 The Rest of the World biopharmaceuticals market size, by country, 2010 – 2013 (USD Mn) 141
TABLE 93 Global biopharmaceuticals market size, by region, 2014 – 2020 (USD Mn) 142
TABLE 94 Brazilian biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 144
TABLE 95 Brazilian biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 145
TABLE 96 Brazilian biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 146
TABLE 97 Brazilian biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 147
TABLE 98 Australian biopharmaceuticals market size, by type, 2010 – 2013 (USD Mn) 149
TABLE 99 Australian biopharmaceuticals market size, by type, 2014 – 2020 (USD Mn) 150
TABLE 100 Australian biopharmaceuticals market size, by therapeutic application, 2010 – 2013 (USD Mn) 151
TABLE 101 Australian biopharmaceuticals market size, by therapeutic application, 2014 – 2020 (USD Mn) 152
TABLE 102 Product categories of Abbott Laboratories 158
TABLE 103 Product category of Pfizer, Inc. 160
TABLE 104 Product category of Eli Lilly and Company 162
TABLE 105 Product categories of Sanofi 164
TABLE 106 Product segment of AbbVie Inc. 167
TABLE 107 Novartis AG’s product categories 170
TABLE 108 AstraZeneca plc’s product categories 172
TABLE 109 Amgen, Inc. product category 175
TABLE 110 Biogen Idec major therapies and their uses 178
TABLE 111 Major product categories of GlaxoSmithKline Plc 182
TABLE 112 Major product categories of Bristol-Myers Squibb Company 185
TABLE 113 Product categories of Bayer AG 187
TABLE 114 Major product categories of Merck & Co., Inc. 190
TABLE 115 Major product categories of Roche 192
TABLE 116 Johnson & Johnson Services, Inc.’s Product Categories 195

FIG. 1 Biopharmaceuticals market: Porter’s five forces analysis 19
FIG. 2 Categorization of Biopharmaceuticals by Type 24
FIG. 3 Categorization of Biopharmaceuticals by Therapeutic Application 25
FIG. 4 Population aged 60 years and above in major countries, 2000 – 2050 26
FIG. 5 Comparison of percentage of Total biopharmaceutical revenues generation by major pharmaceutical companies, 2000 and 2012 29
FIG. 6 Global biopharmaceuticals market share, by region, by value, 2013 37
FIG. 7 Global biopharmaceuticals market share, by type, by value, 2013 39
FIG. 8 Global biopharmaceuticals market share, by therapeutic application, 2013 41
FIG. 9 Global monoclonal antibodies market share, by region, by value, 2013 44
FIG. 10 Global recombinant proteins market share, by region, by value, 2013 46
FIG. 11 Global granulocyte-colony stimulating factor market share, by region, by value, 2013  48
FIG. 12 Global interferons market share, by region, by value, 2013 50
FIG. 13 Global recombinant human insulin market share, by region, by value, 2013 52
FIG. 14 Global erythropoietin market share, by region, by value, 2013 54
FIG. 15 Global vaccines market share, by region, by value, 2013 56
FIG. 16 Global growth hormones market share, by region, by value, 2013 58
FIG. 17 Global purified proteins market share, by region, by value, 2013 60
FIG. 18 Global other market share, by region, by value, 2013 62
FIG. 19 Global metabolic disorders market share, by region, by value, 2013 65
FIG. 20 Global oncology market share, by region, by value, 2013 67
FIG. 21 Global neurological disorders market share, by region, by value, 2013 69
FIG. 22 Global cardiovascular diseases market share, by region, by value, 2013 71
FIG. 23 Global inflammatory and infectious diseases market share, by region, by value, 2013  73
FIG. 24 Global others market share, by region, by value, 2013 75
FIG. 25 North America biopharmaceuticals market share, by country, by value, 2013 78
FIG. 26 The U.S. biopharmaceuticals market share, by type, by value, 2013 80
FIG. 27 The U.S. biopharmaceuticals market share, by therapeutic application, by value, 2013  83
FIG. 28 Canadian biopharmaceuticals market share, by type, by value, 2013 85
FIG. 29 Canadian biopharmaceuticals market share, by therapeutic application, by value, 2013  88
FIG. 30 Europe biopharmaceuticals market share, by country, by value, 2013 91
FIG. 31 The U.K. biopharmaceuticals market share, by type, by value, 2013 94
FIG. 32 The U.K. biopharmaceuticals market share, by therapeutic application, by value, 2013  97
FIG. 33 German biopharmaceuticals market share, by type, by value, 2013 99
FIG. 34 German biopharmaceuticals market share, by therapeutic application, by value, 2013  102
FIG. 35 French biopharmaceuticals market share, by type, by value, 2013 104
FIG. 36 French biopharmaceuticals market share, by therapeutic application, by value, 2013  107
FIG. 37 Russian biopharmaceuticals market share, by type, by value, 2013 109
FIG. 38 Russian biopharmaceuticals market share, by therapeutic application, by value, 2013  112
FIG. 39 Italian biopharmaceuticals market share, by type, by value, 2013 114
FIG. 40 Italian biopharmaceuticals market share, by therapeutic application, by value, 2013 117
FIG. 41 Spanish biopharmaceuticals market share, by type, by value, 2013 119
FIG. 42 Spain biopharmaceuticals market share, by therapeutic application, by value, 2013 122
FIG. 43 Asian biopharmaceuticals market share, by country, by value, 2013 124
FIG. 44 Japanese biopharmaceuticals market share, by type, by value, 2013 126
FIG. 45 Japanese biopharmaceuticals market share, by therapeutic application, by value, 2013  129
FIG. 46 Chinese biopharmaceuticals market share, by type, by value, 2013 131
FIG. 47 Chinese biopharmaceuticals market share, by therapeutic application, by value, 2013  134
FIG. 48 Indian biopharmaceuticals market share, by type, by value, 2013 136
FIG. 49 Indian biopharmaceuticals market share, by therapeutic application, by value, 2013 139
FIG. 50 Rest of the World biopharmaceuticals market share, by country, by value, 2013 141
FIG. 51 Brazilian biopharmaceuticals market share, by type, by value, 2013 143
FIG. 52 Brazilian biopharmaceuticals market share, by therapeutic application, by value, 2013  146
FIG. 53 Australian biopharmaceuticals market share, by type, by value, 2013 148
FIG. 54 Australian biopharmaceuticals market share, by therapeutic application, by value, 2013  151
FIG. 55 Competitive landscape of biopharmaceuticals market, 2014 153
FIG. 56 Global Biopharmaceuticals market, by company 2014 (% share) 155
FIG. 57 Abbott Laboratories net sales and net earnings, 2012 – 2014 (USD Mn) 158
FIG. 58 Pfizer, Inc.’s Total revenue and net income, 2012 – 2014 (USD Mn) 161
FIG. 59 Eli Lilly and Company’s revenue and net income, 2012 – 2014 (USD Mn) 163
FIG. 60 Sanofi’s net sales and net income, 2012 – 2014 (USD Mn) 165
FIG. 61 AbbVie, Inc.’s net sales and net earnings, 2012 – 2014 (USD Mn) 168
FIG. 62 Novartis AG’s net sales and net income, 2012 – 2014 (USD Mn) 170
FIG. 63 AstraZeneca plc revenue and profit, 2012 – 2014 (USD Mn) 173
FIG. 64 Amgen, Inc. revenue and net income 2012 – 2014 (USD Mn) 176
FIG. 65 Biogen Idec revenue and net income 2012 – 2014 (USD Mn) 179
FIG. 66 GlaxoSmithKline plc’s turnover and profit, 2012 – 2014 (USD Mn) 183
FIG. 67 Bristol-Myers Squibb Company’s total revenue and net earnings, 2012 – 2014 (USD Mn) 186
FIG. 68 Bayer AG’s net sales and net income, 2011 – 2013 (USD Mn) 188
FIG. 69 Merck & Co., Inc.’s sales and net income, 2012 – 2014 (USD Mn) 191
FIG. 70 Roche’s sales and net income, 2012 – 2014 (USD Mn) 193
FIG. 71 Johnson & Johnson Services, Inc., net sales and net earnings, 2012 – 2014 (USD Mn) 196